Cargando…

Fingolimod versus interferon beta 1-a: Benefit–harm assessment approach based on TRANSFORMS individual patient data

BACKGROUND: Fingolimod is a disease-modifying drug approved for multiple sclerosis but its benefit–harm balance has never been assessed compared to other active treatments. OBJECTIVES: Our aim was to compare the benefits and harms of fingolimod with interferon beta-1a using individual patient data f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spanu, Alessandra, Aschmann, Hélène E, Kesselring, Jürg, Puhan, Milo A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459487/ https://www.ncbi.nlm.nih.gov/pubmed/36092642 http://dx.doi.org/10.1177/20552173221117784

Ejemplares similares

Large-scale prevention trials could provide stronger evidence for decision-makers: Opportunities to design and report with a focus on the benefit–harm balance
por: Aschmann, Hélène E, et al.
Publicado: (2022)

Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
por: Yebyo, Henock G., et al.
Publicado: (2019)

Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018)

Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
por: Yebyo, Henock G., et al.
Publicado: (2020)

Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment
por: Aschmann, Hélène E, et al.
Publicado: (2019)

A framework for organizing and selecting quantitative approaches for benefit-harm assessment
por: Puhan, Milo A, et al.
Publicado: (2012)

The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population
por: Kapica-Topczewska, Katarzyna, et al.
Publicado: (2019)

Aspirin for Primary Prevention of Cardiovascular Disease and Cancer. A Benefit and Harm Analysis
por: Stegeman, Inge, et al.
Publicado: (2015)

Quantitative benefit–harm assessment for setting research priorities: the example of roflumilast for patients with COPD
por: Puhan, Milo A., et al.
Publicado: (2015)

Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer
por: Puhan, Milo A., et al.
Publicado: (2015)

Mental health of individuals infected with SARS-CoV-2 during mandated isolation and compliance with recommendations—A population-based cohort study
por: Domenghino, Anja, et al.
Publicado: (2022)

Individual-Level Evaluation of the Exposure Notification Cascade in the SwissCovid Digital Proximity Tracing App: Observational Study
por: Ballouz, Tala, et al.
Publicado: (2022)

Individual participant data meta-analysis with mixed-effects transformation models
por: Tamási, Bálint, et al.
Publicado: (2021)

Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab
por: Ottenlinger, Florian M., et al.
Publicado: (2016)

Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study
por: Menges, Dominik, et al.
Publicado: (2021)

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023)

Adherence and Association of Digital Proximity Tracing App Notifications With Earlier Time to Quarantine: Results From the Zurich SARS-CoV-2 Cohort Study
por: Ballouz, Tala, et al.
Publicado: (2021)

<xml><?covid-19-pmc?></xml>Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study
por: Ballouz, Tala, et al.
Publicado: (2023)

Shortcomings in Pharmacy Benefit Forecasting - Interferon Beta Products
por: Rich, Sheldon
Publicado: (2003)

Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
por: Calkwood, Jonathan, et al.
Publicado: (2014)

Depression and anxiety in patients with multiple sclerosis treated with interferon-beta or fingolimod: Role of indoleamine 2,3-dioxygenase and pro-inflammatory cytokines
por: Tauil, Carlos B., et al.
Publicado: (2020)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Social media and internet search data to inform drug utilization: A systematic scoping review
por: Keller, Roman, et al.
Publicado: (2023)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

The Swiss Multiple Sclerosis Registry (SMSR): study protocol of a participatory, nationwide registry to promote epidemiological and patient-centered MS research
por: Steinemann, Nina, et al.
Publicado: (2018)

Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment
por: Menges, Dominik, et al.
Publicado: (2023)

Individuals benefit individual out-group members rather than harm in-group members
por: Kasper, Matthias, et al.
Publicado: (2023)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Antidepressant activity of fingolimod in mice
por: di Nuzzo, Luigi, et al.
Publicado: (2015)

Balancing benefits and harm: Chemical use and bodily transformation among Indonesia's transgender waria
por: Idrus, Nurul Ilmi, et al.
Publicado: (2014)

Inconsistent allocations of harms versus benefits may exacerbate environmental inequality
por: Makov, Tamar, et al.
Publicado: (2020)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Oxidative Stress: Harms and Benefits for Human Health
por: Pizzino, Gabriele, et al.
Publicado: (2017)

Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke
por: Salas-Perdomo, Angélica, et al.
Publicado: (2019)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry
por: Braune, Stefan, et al.
Publicado: (2018)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

TRIOLOGY ACS: No benefit/No harm
por: Elmahdy, Mahmoud Farouk, et al.
Publicado: (2013)

Benefits and harms of mammography screening
por: Løberg, Magnus, et al.
Publicado: (2015)

Intermittent Hypoxia in Childhood: The Harmful Consequences Versus Potential Benefits of Therapeutic Uses
por: Serebrovskaya, Tatiana V., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_9mnprqsftj0n7lhrpbt0tdi4r9